<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36601115</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>17</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Determinants of long COVID among adults hospitalized for SARS-CoV-2 infection: A prospective cohort study.</ArticleTitle><Pagination><StartPage>1038227</StartPage><MedlinePgn>1038227</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1038227</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2022.1038227</ELocationID><Abstract><AbstractText Label="RATIONALE">Factors associated with long-term sequelae emerging after the acute phase of COVID-19 (so called "long COVID") are unclear. Here, we aimed to identify risk factors for the development of COVID-19 sequelae in a prospective cohort of subjects hospitalized for SARS-CoV-2 infection and followed up one year after discharge.</AbstractText><AbstractText Label="METHODS">A total of 324 subjects underwent a comprehensive and multidisciplinary evaluation one year after hospital discharge for COVID-19. A subgroup of 247/324 who consented to donate a blood sample were tested for a panel of circulating cytokines.</AbstractText><AbstractText Label="RESULTS">In 122 patients (37.8%) there was evidence of at least one persisting physical symptom. After correcting for comorbidities and COVID-19 severity, the risk of developing long COVID was lower in the 109 subjects admitted to the hospital in the third wave of the pandemic than in the 215 admitted during the first wave, (OR 0.69, 95%CI 0.51-0.93, p=0.01). Univariable analysis revealed female sex, diffusing capacity of the lungs for carbon monoxide (DLCO) value, body mass index, anxiety and depressive symptoms to be positively associated with COVID-19 sequelae at 1 year. Following logistic regression analysis, DLCO was the only independent predictor of residual symptoms (OR 0.98 CI 95% (0.96-0.99), p=0.01). In the subgroup of subjects with normal DLCO (&gt; 80%), for whom residual lung damage was an unlikely explanation for long COVID, the presence of anxiety and depressive symptoms was significantly associated to persistent symptoms, together with increased levels of a set of pro-inflammatory cytokines: interferon-gamma, tumor necrosis factor-alpha, interleukin (IL)-2, IL-12, IL-1&#x3b2;, IL-17. In logistic regression analysis, depressive symptoms (p=0.02, OR 4.57 [1.21-17.21]) and IL-12 levels (p=0.03, OR 1.06 [1.00-1.11]) 1-year after hospital discharge were independently associated with persistence of symptoms.</AbstractText><AbstractText Label="CONCLUSIONS">Long COVID appears mainly related to respiratory sequelae, prevalently observed during the first pandemic wave. Among patients with little or no residual lung damage, a cytokine pattern consistent with systemic inflammation is in place.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Bellan, Apostolo, Alb&#xe8;, Crevola, Errica, Ratano, Tonello, Minisini, D&#x2019;Onghia, Baricich, Patrucco, Zeppegno, Gramaglia, Balbo, Cappellano, Casella, Chiocchetti, Clivati, Giordano, Manfredi, Patti, Pinato, Puricelli, Raineri, Rolla, Sainaghi, Pirisi and the No-More COVID study group.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bellan</LastName><ForeName>Mattia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Universit&#xe0; del Piemonte Orientale (UPO), Novara, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>"AOU Maggiore della Carit&#xe0;", Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Apostolo</LastName><ForeName>Daria</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Universit&#xe0; del Piemonte Orientale (UPO), Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alb&#xe8;</LastName><ForeName>Alice</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Universit&#xe0; del Piemonte Orientale (UPO), Novara, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>"AOU Maggiore della Carit&#xe0;", Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crevola</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Universit&#xe0; del Piemonte Orientale (UPO), Novara, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>"AOU Maggiore della Carit&#xe0;", Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Errica</LastName><ForeName>Nicol&#xf2;</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Universit&#xe0; del Piemonte Orientale (UPO), Novara, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>"AOU Maggiore della Carit&#xe0;", Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ratano</LastName><ForeName>Giacomo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Universit&#xe0; del Piemonte Orientale (UPO), Novara, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>"AOU Maggiore della Carit&#xe0;", Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tonello</LastName><ForeName>Stelvio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Universit&#xe0; del Piemonte Orientale (UPO), Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minisini</LastName><ForeName>Rosalba</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Universit&#xe0; del Piemonte Orientale (UPO), Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Onghia</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Universit&#xe0; del Piemonte Orientale (UPO), Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baricich</LastName><ForeName>Alessio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Universit&#xe0; del Piemonte Orientale (UPO), Novara, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>"AOU Maggiore della Carit&#xe0;", Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patrucco</LastName><ForeName>Filippo</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Universit&#xe0; del Piemonte Orientale (UPO), Novara, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>"AOU Maggiore della Carit&#xe0;", Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeppegno</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Universit&#xe0; del Piemonte Orientale (UPO), Novara, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>"AOU Maggiore della Carit&#xe0;", Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gramaglia</LastName><ForeName>Carla</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Universit&#xe0; del Piemonte Orientale (UPO), Novara, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>"AOU Maggiore della Carit&#xe0;", Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balbo</LastName><ForeName>Piero Emilio</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>"AOU Maggiore della Carit&#xe0;", Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cappellano</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Universit&#xe0; del Piemonte Orientale (UPO), Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casella</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Universit&#xe0; del Piemonte Orientale (UPO), Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiocchetti</LastName><ForeName>Annalisa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Universit&#xe0; del Piemonte Orientale (UPO), Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clivati</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>"AOU Maggiore della Carit&#xe0;", Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giordano</LastName><ForeName>Mara</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Universit&#xe0; del Piemonte Orientale (UPO), Novara, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>"AOU Maggiore della Carit&#xe0;", Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manfredi</LastName><ForeName>Marcello</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Universit&#xe0; del Piemonte Orientale (UPO), Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patti</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Universit&#xe0; del Piemonte Orientale (UPO), Novara, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>"AOU Maggiore della Carit&#xe0;", Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinato</LastName><ForeName>David James</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Universit&#xe0; del Piemonte Orientale (UPO), Novara, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puricelli</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Universit&#xe0; del Piemonte Orientale (UPO), Novara, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>"AOU Maggiore della Carit&#xe0;", Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raineri</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Universit&#xe0; del Piemonte Orientale (UPO), Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rolla</LastName><ForeName>Roberta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Universit&#xe0; del Piemonte Orientale (UPO), Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sainaghi</LastName><ForeName>Pier Paolo</ForeName><Initials>PP</Initials><AffiliationInfo><Affiliation>Universit&#xe0; del Piemonte Orientale (UPO), Novara, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>"AOU Maggiore della Carit&#xe0;", Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pirisi</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Universit&#xe0; del Piemonte Orientale (UPO), Novara, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>"AOU Maggiore della Carit&#xe0;", Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>No-More COVID study group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>187348-17-0</RegistryNumber><NameOfSubstance UI="D018664">Interleukin-12</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018664" MajorTopicYN="N">Interleukin-12</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DLCO</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 infection</Keyword><Keyword MajorTopicYN="N">cytokines</Keyword><Keyword MajorTopicYN="N">depression</Keyword><Keyword MajorTopicYN="N">long COVID-19</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Bellan</LastName><ForeName>Mattia</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Apostolo</LastName><ForeName>Daria</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alb&#xe8;</LastName><ForeName>Alice</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crevola</LastName><ForeName>Martina</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nicol&#xf2;</LastName><ForeName>Errica</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ratano</LastName><ForeName>Giacomo</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Acquavivas</LastName><ForeName>Antonio</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Castello</LastName><ForeName>Luigi Mario</ForeName><Initials>LM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tonello</LastName><ForeName>Stelvio</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Minisini</LastName><ForeName>Rosalba</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>D'Onghia</LastName><ForeName>Davide</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baricich</LastName><ForeName>Alessio</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patrucco</LastName><ForeName>Filippo</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zeppegno</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gramaglia</LastName><ForeName>Carla</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Avanzi</LastName><ForeName>Gian Carlo</ForeName><Initials>GC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Balbo</LastName><ForeName>Piero Emilio</ForeName><Initials>PE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baldon</LastName><ForeName>Giulia</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barini</LastName><ForeName>Michela</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Battaglia</LastName><ForeName>Marco</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bor</LastName><ForeName>Simone</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cantaluppi</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cappellano</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carriero</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Casella</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chiocchetti</LastName><ForeName>Annalisa</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cuneo</LastName><ForeName>Daria</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gambaro</LastName><ForeName>Eleonora</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giordano</LastName><ForeName>Mara</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Isabella</LastName><ForeName>Luisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loro</LastName><ForeName>Alberto</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marangon</LastName><ForeName>Debora</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mones</LastName><ForeName>Emanuele</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paracchini</LastName><ForeName>Elena</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patti</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pinato</LastName><ForeName>David James</ForeName><Initials>DJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Puricelli</LastName><ForeName>Chiara</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raineri</LastName><ForeName>Davide</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rolla</LastName><ForeName>Roberta</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sainaghi</LastName><ForeName>Pier Paolo</ForeName><Initials>PP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tricca</LastName><ForeName>Stefano</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pirisi</LastName><ForeName>Mario</ForeName><Initials>M</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>5</Day><Hour>2</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36601115</ArticleId><ArticleId IdType="pmc">PMC9807078</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.1038227</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mehandru S, Merad M. Pathological sequelae of long-haul COVID. Nat Immunol (2022) 23:194&#x2013;202. doi: 10.1038/s41590-021-01104-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01104-y</ArticleId><ArticleId IdType="pmc">PMC9127978</ArticleId><ArticleId IdType="pubmed">35105985</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellan M, Soddu D, Balbo PE, Baricich A, Zeppegno P, Avanzi GC, et al. . Respiratory and psychophysical sequelae among patients with COVID-19 four months after hospital discharge. JAMA Netw Open (2021) 4:e2036142. doi: 10.1001/jamanetworkopen.2020.36142</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.36142</ArticleId><ArticleId IdType="pmc">PMC7841464</ArticleId><ArticleId IdType="pubmed">33502487</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Li X, Gu X, Zhang H, Ren L, Guo L, et al. . Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med (2022) 10(9):863&#x2013;76. doi: 10.1016/S2213-2600(22)00126-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00126-6</ArticleId><ArticleId IdType="pmc">PMC9094732</ArticleId><ArticleId IdType="pubmed">35568052</ArticleId></ArticleIdList></Reference><Reference><Citation>
National Institute for Health and Care Excellence . COVID-19 rapid guideline: managing the long-term effects of COVID-19 NICE guideline (2020). Available at: https://www.nice.org.uk/guidance/ng188/chapter/Recommendations.</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. BMJ (2021) 374:n1648. doi: 10.1136/bmj.n1648</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. . Post-acute COVID-19 syndrome. Nat Med (2021) 27:601&#x2013;15. doi: 10.1038/s41591-021-01283-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Sullivan O. Long-term sequelae following previous coronavirus epidemics. Clin Med (2021) 21:e68&#x2013;70. doi: 10.7861/clinmed.2020-0204</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmed.2020-0204</ArticleId><ArticleId IdType="pmc">PMC7850177</ArticleId><ArticleId IdType="pubmed">33144403</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of COVID-19. Science (2022) 375:1122&#x2013;7. doi: 10.1126/science.abm8108</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm8108</ArticleId><ArticleId IdType="pubmed">35271343</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavli A, Theodoridou M, Maltezou HC. Post-COVID syndrome: Incidence, clinical spectrum, and challenges for primary healthcare professionals. Arch Med Res (2021) 52:575&#x2013;81. doi: 10.1016/j.arcmed.2021.03.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arcmed.2021.03.010</ArticleId><ArticleId IdType="pmc">PMC8093949</ArticleId><ArticleId IdType="pubmed">33962805</ArticleId></ArticleIdList></Reference><Reference><Citation>Castanares-Zapatero D, Chalon P, Kohn L, Dauvrin M, Detollenaere J, Maertens de Noordhout C, et al. . Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med (2022) 54:1473&#x2013;87. doi: 10.1080/07853890.2022.2076901</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2022.2076901</ArticleId><ArticleId IdType="pmc">PMC9132392</ArticleId><ArticleId IdType="pubmed">35594336</ArticleId></ArticleIdList></Reference><Reference><Citation>Girija ASS, Shankar EM, Larsson M. Could SARS-CoV-2-Induced hyperinflammation magnify the severity of coronavirus disease (CoViD-19) leading to acute respiratory distress syndrome? Front Immunol (2020) 11. doi: 10.3389/fimmu.2020.01206</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01206</ArticleId><ArticleId IdType="pmc">PMC7267050</ArticleId><ArticleId IdType="pubmed">32574269</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson JG, Simpson LJ, Ferreira AM, Rustagi A, Roque J, Asuni A, et al. . Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis. JCI Insight (2020) 5:e140289. doi: 10.1172/jci.insight.140289</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.140289</ArticleId><ArticleId IdType="pmc">PMC7526438</ArticleId><ArticleId IdType="pubmed">32706339</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghazavi A, Ganji A, Keshavarzian N, Rabiemajd S, Mosayebi G. Cytokine profile and disease severity in patients with COVID-19. Cytokine (2021) 137:155323. doi: 10.1016/j.cyto.2020.155323</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2020.155323</ArticleId><ArticleId IdType="pmc">PMC7524708</ArticleId><ArticleId IdType="pubmed">33045526</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardone M, Yano M, Rosenberg AS, Puig M. Lessons learned to date on COVID-19 hyperinflammatory syndrome: Considerations for interventions to mitigate SARS-CoV-2 viral infection and detrimental hyperinflammation. Front Immunol (2020) 11. doi: 10.3389/fimmu.2020.01131</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01131</ArticleId><ArticleId IdType="pmc">PMC7272717</ArticleId><ArticleId IdType="pubmed">32574265</ArticleId></ArticleIdList></Reference><Reference><Citation>Salton F, Confalonieri P, Campisciano G, Cifaldi R, Rizzardi C, Generali D, et al. . Cytokine profiles as potential prognostic and therapeutic markers in SARS-CoV-2-Induced ARDS. J Clin Med (2022) 11:2951. doi: 10.3390/jcm11112951</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11112951</ArticleId><ArticleId IdType="pmc">PMC9180983</ArticleId><ArticleId IdType="pubmed">35683340</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortellini A, Gennari A, Pommeret F, Patel G, Newsom-Davis T, Bertuzzi A, et al. . COVID-19 sequelae and the host proinflammatory response: An analysis from the OnCovid registry. J Natl Cancer Inst (2022) 114:979&#x2013;87. doi: 10.1093/jnci/djac057</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/djac057</ArticleId><ArticleId IdType="pmc">PMC9047221</ArticleId><ArticleId IdType="pubmed">35417006</ArticleId></ArticleIdList></Reference><Reference><Citation>Baratella E, Ruaro B, Marrocchio C, Starvaggi N, Salton F, Giudici F, et al. . Interstitial lung disease at high resolution ct after sars-cov-2-related acute respiratory distress syndrome according to pulmonary segmental anatomy. J Clin Med (2021) 10:3985. doi: 10.3390/jcm10173985</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10173985</ArticleId><ArticleId IdType="pmc">PMC8432464</ArticleId><ArticleId IdType="pubmed">34501430</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaroff AL, Lipkin WI. Insights from myalgic encephalomyelitis/chronic fatigue syndrome may help unravel the pathogenesis of postacute COVID-19 syndrome. Trends Mol Med (2021) 27:895&#x2013;906. doi: 10.1016/j.molmed.2021.06.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2021.06.002</ArticleId><ArticleId IdType="pmc">PMC8180841</ArticleId><ArticleId IdType="pubmed">34175230</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier C, Patel SK, et al. . Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol (2022) 23:210&#x2013;6. doi: 10.1038/s41590-021-01113-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta-Ampudia Y, Monsalve DM, Rojas M, Rodr&#xed;guez Y, Zapata E, Ram&#xed;rez-Santana C, et al. . Persistent autoimmune activation and proinflammatory state in post-coronavirus disease 2019 syndrome. J Infect Dis (2022) 225:2155&#x2013;62. doi: 10.1093/infdis/jiac017</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac017</ArticleId><ArticleId IdType="pmc">PMC8903340</ArticleId><ArticleId IdType="pubmed">35079804</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. . Remdesivir for the treatment of covid-19 - final report. N Eng J Med (2020) 383:1813&#x2013;26. doi: 10.1056/NEJMoa2007764</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2007764</ArticleId><ArticleId IdType="pmc">PMC7262788</ArticleId><ArticleId IdType="pubmed">32445440</ArticleId></ArticleIdList></Reference><Reference><Citation>Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc (1968) 16:622&#x2013;6. doi: 10.1111/j.1532-5415.1968.tb02103.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.1968.tb02103.x</ArticleId><ArticleId IdType="pubmed">5646906</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. . The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Clin Psych (1998) 59 S20:22&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">9881538</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellan M, Baricich A, Patrucco F, Zeppegno P, Gramaglia C, Balbo PE, et al. . Long-term sequelae are highly prevalent one year after hospitalization for severe COVID-19. Sci Rep (2021) 11:22666. doi: 10.1038/s41598-021-01215-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-01215-4</ArticleId><ArticleId IdType="pmc">PMC8608998</ArticleId><ArticleId IdType="pubmed">34811387</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y, et al. . Clinical sequelae of COVID-19 survivors in wuhan, China: a single-centre longitudinal study. Clin Microbiol Infect (2021) 27:89&#x2013;95. doi: 10.1016/j.cmi.2020.09.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.09.023</ArticleId><ArticleId IdType="pmc">PMC7510771</ArticleId><ArticleId IdType="pubmed">32979574</ArticleId></ArticleIdList></Reference><Reference><Citation>Fumagalli C, Zocchi C, Tassetti L, Silverii MV, Amato C, Livi L, et al. . Factors associated with persistence of symptoms 1 year after COVID-19: A longitudinal, prospective phone-based interview follow-up cohort study. Eur J Int Med (2022) 97:36&#x2013;41. doi: 10.1016/j.ejim.2021.11.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2021.11.018</ArticleId><ArticleId IdType="pmc">PMC8648678</ArticleId><ArticleId IdType="pubmed">34903448</ArticleId></ArticleIdList></Reference><Reference><Citation>Lombardo M, Foppiani A, Peretti GM, Mangiavini L, Battezzati A, Bertoli S, et al. . Long-term coronavirus disease 2019 complications in inpatients and outpatients: A one-year follow-up cohort study. Open Forum Infect Dis (2021) 8:ofab384. doi: 10.1093/ofid/ofab384</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab384</ArticleId><ArticleId IdType="pmc">PMC8344801</ArticleId><ArticleId IdType="pubmed">34386546</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellan M, Patti G, Hayden E, Azzolina D, Pirisi M, Acquaviva A, et al. . Fatality rate and predictors of mortality in an Italian cohort of hospitalized COVID-19 patients. Sci Rep (2020) 10:20731. doi: 10.1038/s41598-020-77698-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-77698-4</ArticleId><ArticleId IdType="pmc">PMC7692524</ArticleId><ArticleId IdType="pubmed">33244144</ArticleId></ArticleIdList></Reference><Reference><Citation>Bechman K, Yates M, Mann K, Nagra D, Smith LJ, Rutherford AI, et al. . Inpatient COVID-19 mortality has reduced over time: Results from an observational cohort. PloS One (2022) 17(1):e0261142. doi: 10.1371/journal.pone.0261142</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0261142</ArticleId><ArticleId IdType="pmc">PMC8757902</ArticleId><ArticleId IdType="pubmed">35025917</ArticleId></ArticleIdList></Reference><Reference><Citation>Twohig KA, Nyberg T, Zaidi A, Thelwall S, Sinnathamby MA, Aliabadi S, et al. . Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect Dis (2022) 22:35&#x2013;42. doi: 10.1016/S1473-3099(21)00475-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00475-8</ArticleId><ArticleId IdType="pmc">PMC8397301</ArticleId><ArticleId IdType="pubmed">34461056</ArticleId></ArticleIdList></Reference><Reference><Citation>Cort&#xe9;s-Telles A, L&#xf3;pez-Romero S, Figueroa-Hurtado E, Pou-Aguilar YN, Wong AW, Milne KM, et al. . Pulmonary function and functional capacity in COVID-19 survivors with persistent dyspnoea. Respir Physiol Neurobiol (2021) 288:103644. doi: 10.1016/j.resp.2021.103644</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resp.2021.103644</ArticleId><ArticleId IdType="pmc">PMC7910142</ArticleId><ArticleId IdType="pubmed">33647535</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai F, Tomasoni D, Falcinella C, Barbanotti D, Castoldi R, Mul&#xe8; G, et al. . Female gender is associated with long COVID syndrome: a prospective cohort study. Clin Microbiol Infect (2022) 28:611.e9&#x2013;611.e16. doi: 10.1016/j.cmi.2021.11.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.11.002</ArticleId><ArticleId IdType="pmc">PMC8575536</ArticleId><ArticleId IdType="pubmed">34763058</ArticleId></ArticleIdList></Reference><Reference><Citation>Vimercati L, De Maria L, Quarato M, Caputi A, Gesualdo L, Migliore G, et al. . Association between long COVID and Overweight/Obesity. J Clin Med (2021) 10:4143. doi: 10.3390/jcm10184143</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10184143</ArticleId><ArticleId IdType="pmc">PMC8469321</ArticleId><ArticleId IdType="pubmed">34575251</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam MS, Ferdous MZ, Islam US, Mosaddek A, Potenza MN, Pardhan S. Treatment, persistent symptoms, and depression in people infected with COVID-19 in Bangladesh. Int J Environ Res Public Health (2021) 18:1453. doi: 10.3390/ijerph18041453</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph18041453</ArticleId><ArticleId IdType="pmc">PMC7914967</ArticleId><ArticleId IdType="pubmed">33562427</ArticleId></ArticleIdList></Reference><Reference><Citation>Gramaglia C, Gambaro E, Bellan M, Balbo PE, Baricich A, Sainaghi PP, et al. . Mid-term psychiatric outcomes of patients recovered from COVID-19 from an Italian cohort of hospitalized patients. Front Psychiatry (2021) 12:667385. doi: 10.3389/fpsyt.2021.667385</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2021.667385</ArticleId><ArticleId IdType="pmc">PMC8222628</ArticleId><ArticleId IdType="pubmed">34177656</ArticleId></ArticleIdList></Reference><Reference><Citation>Gramaglia C, Gattoni E, Gambaro E, Bellan M, Balbo PE, Baricich A, et al. . Anxiety, stress and depression in COVID-19 survivors from an Italian cohort of hospitalized patients: Results from a 1-year follow-up. Front Psychiatry (2022) 13:862651. doi: 10.3389/fpsyt.2022.862651</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2022.862651</ArticleId><ArticleId IdType="pmc">PMC9247238</ArticleId><ArticleId IdType="pubmed">35782424</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirschenberger M, Hunszinger V, Sparrer K. Implications of innate immunity in post-acute sequelae of non-persistent viral infections. Cells (2021) 10:2134. doi: 10.3390/cells10082134</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10082134</ArticleId><ArticleId IdType="pmc">PMC8391718</ArticleId><ArticleId IdType="pubmed">34440903</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannakodimos I, Gkountana GV, Lykouras D, Karkoulias K, Tsakas S. The role of interleukin-6 in the pathogenesis, prognosis and treatment of severe COVID-19. Curr Med Chem (2021) 28:5328&#x2013;38. doi: 10.2174/0929867328666201209100259</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867328666201209100259</ArticleId><ArticleId IdType="pubmed">33297909</ArticleId></ArticleIdList></Reference><Reference><Citation>Queiroz M, Neves P, Lima SS, Lopes J, Torres M, Vallinoto I, et al. . Cytokine profiles associated with acute COVID-19 and long COVID-19 syndrome. Front Cell Infect Microbiol (2022) 12:922422. doi: 10.3389/fcimb.2022.922422</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.922422</ArticleId><ArticleId IdType="pmc">PMC9279918</ArticleId><ArticleId IdType="pubmed">35846757</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulthei&#xdf; C, Willscher E, Paschold L, Gottschick C, Klee B, Henkes SS, et al. . The IL-1&#x3b2;, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep Med (2022) 3:100663. doi: 10.1016/j.xcrm.2022.100663</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100663</ArticleId><ArticleId IdType="pmc">PMC9214726</ArticleId><ArticleId IdType="pubmed">35732153</ArticleId></ArticleIdList></Reference><Reference><Citation>Tait Wojno ED, Hunter CA, Stumhofer JS. The immunobiology of the interleukin-12 family: Room for discovery. Immunity (2019) 50:851&#x2013;70. doi: 10.1016/j.immuni.2019.03.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.03.011</ArticleId><ArticleId IdType="pmc">PMC6472917</ArticleId><ArticleId IdType="pubmed">30995503</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen B, Tosti A. Alopecia in patients with COVID-19: A systematic review and meta-analysis. JAAD Int (2022) 7:67&#x2013;77. doi: 10.1016/j.jdin.2022.02.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdin.2022.02.006</ArticleId><ArticleId IdType="pmc">PMC8860672</ArticleId><ArticleId IdType="pubmed">35224518</ArticleId></ArticleIdList></Reference><Reference><Citation>Wa&#x15b;kiel-Burnat A, Osi&#x144;ska M, Sali&#x144;ska A, Blicharz L, Goldust M, Olszewska M, et al. . The role of serum Th1, Th2, and Th17 cytokines in patients with alopecia areata: Clinical implications. Cells (2021) 10:3397. doi: 10.3390/cells10123397</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10123397</ArticleId><ArticleId IdType="pmc">PMC8699846</ArticleId><ArticleId IdType="pubmed">34943905</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibrahim O, Bayart CB, Hogan S, Piliang M, Bergfeld WF. Treatment of alopecia areata with tofacitinib. JAMA Dermatol (2017) 153:600&#x2013;2. doi: 10.1001/jamadermatol.2017.0001</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamadermatol.2017.0001</ArticleId><ArticleId IdType="pmc">PMC5817614</ArticleId><ArticleId IdType="pubmed">28355451</ArticleId></ArticleIdList></Reference><Reference><Citation>A&#x15f;k&#x131;n &#xd6;, Y&#xfc;cesoy SN, Co&#x15f;kun E, Engin B, Serdaro&#x11f;lu S. Evaluation of the level of serum interleukins (IL-2, IL-4, IL-15 andIL-17) and its relationship with disease severity in patients with alopecia areata. Bras Dermatol (2021) 96:551&#x2013;7. doi: 10.1016/j.abd.2021.03.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.abd.2021.03.006</ArticleId><ArticleId IdType="pmc">PMC8441470</ArticleId><ArticleId IdType="pubmed">34281739</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>